CN109640998A - 治疗昼夜节律性睡眠障碍的方法 - Google Patents

治疗昼夜节律性睡眠障碍的方法 Download PDF

Info

Publication number
CN109640998A
CN109640998A CN201780039758.8A CN201780039758A CN109640998A CN 109640998 A CN109640998 A CN 109640998A CN 201780039758 A CN201780039758 A CN 201780039758A CN 109640998 A CN109640998 A CN 109640998A
Authority
CN
China
Prior art keywords
compound
formula
sleep
subject
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780039758.8A
Other languages
English (en)
Chinese (zh)
Inventor
C.T.贝克曼
M.莫林
A.萨特林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wei Wei Research Development Management Co Ltd
Original Assignee
Wei Wei Research Development Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wei Wei Research Development Management Co Ltd filed Critical Wei Wei Research Development Management Co Ltd
Publication of CN109640998A publication Critical patent/CN109640998A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201780039758.8A 2016-05-12 2017-05-11 治疗昼夜节律性睡眠障碍的方法 Pending CN109640998A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662335611P 2016-05-12 2016-05-12
US201662335599P 2016-05-12 2016-05-12
US62/335,599 2016-05-12
US62/335,611 2016-05-12
US201662413976P 2016-10-27 2016-10-27
US62/413,976 2016-10-27
US201662414599P 2016-10-28 2016-10-28
US201662414606P 2016-10-28 2016-10-28
US62/414,599 2016-10-28
US62/414,606 2016-10-28
PCT/US2017/032228 WO2017197160A1 (en) 2016-05-12 2017-05-11 Methods of treating circadian rhythm sleep disorders

Publications (1)

Publication Number Publication Date
CN109640998A true CN109640998A (zh) 2019-04-16

Family

ID=58745465

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780039758.8A Pending CN109640998A (zh) 2016-05-12 2017-05-11 治疗昼夜节律性睡眠障碍的方法

Country Status (16)

Country Link
US (2) US11096941B2 (enExample)
EP (2) EP4056180A1 (enExample)
JP (2) JP6888026B2 (enExample)
KR (2) KR20230043227A (enExample)
CN (1) CN109640998A (enExample)
AU (3) AU2017264871B2 (enExample)
CA (1) CA3022068A1 (enExample)
ES (1) ES2904625T3 (enExample)
IL (2) IL291791B2 (enExample)
MX (1) MX379318B (enExample)
MY (1) MY199382A (enExample)
RU (1) RU2763493C2 (enExample)
SG (1) SG11201809527UA (enExample)
TW (1) TWI795359B (enExample)
WO (1) WO2017197160A1 (enExample)
ZA (1) ZA201807903B (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111450076A (zh) * 2020-05-25 2020-07-28 安徽省逸欣铭医药科技有限公司 一种Lemborexant软胶囊组合物及其制备方法
CN114159568A (zh) * 2020-09-11 2022-03-11 北京原基华毅生物科技有限公司 Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用
CN114502167A (zh) * 2019-09-13 2022-05-13 卫材R&D管理有限公司 用于治疗失眠的药物组合物
CN114901285A (zh) * 2020-01-16 2022-08-12 卫材R&D管理有限公司 莱博雷生的原料药及含有其的医药组合物
WO2023130675A1 (zh) * 2022-01-04 2023-07-13 中国科学院脑科学与智能技术卓越创新中心 Isx-9在治疗衰老相关的昼夜节律幅度下降和睡眠障碍方面的应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3022068A1 (en) * 2016-05-12 2017-11-16 Eisai R&D Management Co., Ltd. Methods of treating circadian rhythm sleep disorders
AU2020307991A1 (en) * 2019-06-26 2022-02-10 Eisai R&D Management Co., Ltd. Lemborexant for treating sleep issues
JP2022538170A (ja) * 2019-06-26 2022-08-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 睡眠問題の治療のためのレンボレキサント
WO2020263253A1 (en) * 2019-06-26 2020-12-30 Moline Margaret Lemborexant for treating sleep issues
JP2023506025A (ja) * 2019-12-11 2023-02-14 テバ チェコ インダストリーズ エス．アール．オー． レンボレキサントの固体形態
EP4376954A1 (en) * 2021-07-26 2024-06-05 Eisai R&D Management Co., Ltd. Lemborexant for use in methods of treating irregular sleep-wake rhythm disorder and circadian rhythm sleep disorders associated with neurodegenerative diseases
TW202425995A (zh) 2022-09-23 2024-07-01 日商衛材R&D企管股份有限公司 減少與神經退化疾病相關的神經退化的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101511833A (zh) * 2006-08-28 2009-08-19 埃科特莱茵药品有限公司 1,4,5,6,7,8-六氢-1,2,5-三氮杂-甘菊环烃衍生物
CN104220065A (zh) * 2012-02-07 2014-12-17 Eolas治疗公司 取代的脯氨酸/哌啶用作食欲素受体拮抗剂
WO2016063995A1 (en) * 2014-10-23 2016-04-28 Eisai R&D Management Co., Ltd. Compositions and methods for treating insomnia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1715742A4 (en) 2004-02-20 2009-06-17 Lifescape Biosciences Inc COMPOSITIONS AND METHODS FOR SLEEPING
SI2626350T1 (sl) 2010-09-22 2015-09-30 Eisai R&D Management Co., Ltd. Spojina ciklopropana
CA3022068A1 (en) 2016-05-12 2017-11-16 Eisai R&D Management Co., Ltd. Methods of treating circadian rhythm sleep disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101511833A (zh) * 2006-08-28 2009-08-19 埃科特莱茵药品有限公司 1,4,5,6,7,8-六氢-1,2,5-三氮杂-甘菊环烃衍生物
CN104220065A (zh) * 2012-02-07 2014-12-17 Eolas治疗公司 取代的脯氨酸/哌啶用作食欲素受体拮抗剂
WO2016063995A1 (en) * 2014-10-23 2016-04-28 Eisai R&D Management Co., Ltd. Compositions and methods for treating insomnia

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHRISTOPH BOSS: "Recent trends in orexin research—2010 to 2015", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *
MAAN GEE LEE: "Discharge of Identified Orexin/Hypocretin Neurons across the Sleep–Waking Cycle", 《THE JOURNAL OF NEUROSCIENCE》 *
YU YOSHIDA ET AL: "Discovery of (1R,2S)‑2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)‑N‑(5-fluoropyridin-2-yl)cyclopropanecarboxamide(E2006):A Potent and Efficacious Oral Orexin Receptor Antagonist", 《JOURNAL OF MEDICINAL CHEMISTRY》 *
唐丽娜: "Orexin与睡眠-觉醒调节", 《国际药学研究杂质》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114502167A (zh) * 2019-09-13 2022-05-13 卫材R&D管理有限公司 用于治疗失眠的药物组合物
CN114901285A (zh) * 2020-01-16 2022-08-12 卫材R&D管理有限公司 莱博雷生的原料药及含有其的医药组合物
CN111450076A (zh) * 2020-05-25 2020-07-28 安徽省逸欣铭医药科技有限公司 一种Lemborexant软胶囊组合物及其制备方法
CN114159568A (zh) * 2020-09-11 2022-03-11 北京原基华毅生物科技有限公司 Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用
WO2023130675A1 (zh) * 2022-01-04 2023-07-13 中国科学院脑科学与智能技术卓越创新中心 Isx-9在治疗衰老相关的昼夜节律幅度下降和睡眠障碍方面的应用

Also Published As

Publication number Publication date
NZ748555A (en) 2025-06-27
JP2021120410A (ja) 2021-08-19
RU2018143809A3 (enExample) 2020-09-17
MX2018013663A (es) 2019-07-18
AU2017264871A1 (en) 2018-11-15
EP3454859A1 (en) 2019-03-20
JP6888026B2 (ja) 2021-06-16
IL291791A (en) 2022-06-01
US20210353625A1 (en) 2021-11-18
MY199382A (en) 2023-10-25
IL262803A (en) 2018-12-31
WO2017197160A1 (en) 2017-11-16
MX379318B (es) 2025-03-10
JP7150096B2 (ja) 2022-10-07
IL291791B2 (en) 2025-09-01
EP3454859B1 (en) 2021-12-01
US11096941B2 (en) 2021-08-24
CA3022068A1 (en) 2017-11-16
RU2763493C2 (ru) 2021-12-29
SG11201809527UA (en) 2018-11-29
AU2017264871B2 (en) 2023-03-16
KR20230043227A (ko) 2023-03-30
TW201740952A (zh) 2017-12-01
RU2018143809A (ru) 2020-06-15
AU2025205336A1 (en) 2025-07-31
EP4056180A1 (en) 2022-09-14
KR20190013820A (ko) 2019-02-11
AU2023203418A1 (en) 2023-06-29
ZA201807903B (en) 2021-04-28
US20200179382A1 (en) 2020-06-11
JP2019518732A (ja) 2019-07-04
BR112018073037A2 (pt) 2019-02-26
IL291791B1 (en) 2025-05-01
IL262803B (en) 2022-05-01
TWI795359B (zh) 2023-03-11
ES2904625T3 (es) 2022-04-05
KR102511855B1 (ko) 2023-03-20

Similar Documents

Publication Publication Date Title
CN109640998A (zh) 治疗昼夜节律性睡眠障碍的方法
ES2843952T3 (es) Composiciones para tratar el insomnio
JP2018184440A (ja) うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
US20220110949A1 (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
US20220305012A1 (en) Lemborexant for treating sleep issues
RU2844395C2 (ru) Лемборексант для лечения проблем со сном
US20250064802A1 (en) Methods of treating irregular sleep-wake rhythm disorder and circadian rhythm sleep disorders associated with neurodegenerative diseases
EP3989976A1 (en) Lemborexant for treating sleep issues
WO2020263331A1 (en) Lemborexant for treating sleep issues
HK40007283A (en) Methods of treating circadian rhythm sleep disorders
JP2025116005A (ja) 睡眠問題の治療のためのレンボレキサント
BR112018073037B1 (pt) Uso de um composto
BR122024003210A2 (pt) Uso de um composto
NZ787958A (en) Methods of treating circadian rhythm sleep disorders
KR20100092346A (ko) 이산화규소(Sio2)를 유효성분으로 함유하는 치매증상 개선용 조성물
Xu et al. Case Report Crying seizures without tears and amygdaloid lesions: a case report

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40007283

Country of ref document: HK